BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Activating point mutations of the BRAF gene have been recently reported in papillary thyroid carcinomas. In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell lines and detected BRAF mutations in 45 (38%) papillary carcinomas, two (13%) poorly-differentiated carcinomas, three (10%) anaplastic carcinomas, and five (83%) thyroid anaplastic carcinoma cell lines but not in follicular, Hürthle cell, and medullary carcinomas, follicular and Hürthle cell adenomas, or benign hyperplastic nodules. All mutations involved a T→A transversion at nucleotide 1796. In papillary carcinomas, BRAF mutations were associated with older age, classic papillary carcinoma or tall cell variant histology, extrathyroidal extension, and more frequent presentation at stages III and IV. All BRAF-positive poorly differentiated and anaplastic carcinomas contained areas of preexisting papillary carcinoma, and mutation was present in both the well-differentiated and dedifferentiated components. These data indicate that BRAF mutations are restricted to papillary carcinomas and poorly differentiated and anaplastic carcinomas arising from papillary carcinomas. They are associated with distinct phenotypical and biological properties of papillary carcinomas and may participate in progression to poorly differentiated and anaplastic carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 6×
“00/0 The Journal of Clinical Endocrinology & Metabolism 88(11):5399–5404 Printed in U.”
BackgroundInfluentialFirminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
AJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Self-citationRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“Nucleotide 1796, the only mutational site in thyroid carcinomas, was the most frequently affected hot spot in other types of human cancers where BRAF is mutated, such as malignant melanoma and colorectal carcinoma (11, 12).”
BackgroundBRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Rosaí, J., Carcangiu, M. L., & DeLellis, R. A. (1992) · Armed Forces Institute of Pathology eBooks · Cited by 669
Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases
Venkatesh, Y. S. S., Ordonez, N. G., Schultz, P. N., Hickey, R. C., Goepfert, H., & Samaan, N. A. (1990) · Cancer · doi:10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a · Cited by 486
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Williams, E. D., Goyns, M. H., Stringer, B. M. J., & Wynford‐Thomas, D. (1989) · PubMed · Cited by 417
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
“The BRAF mutation is found in *80% of these tumors (156,466).”
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Self-citationBRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Self-citationThe role of microRNA genes in papillary thyroid carcinoma
He, H., Jazdzewski, K., Li, W., Liyanarachchi, S., Nagy, R., Volinia, S., Calin, G. A., Liu, C.-G., Franssila, K., Suster, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509603102 · Cited by 1,215
Molecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Self-citationBRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Self-citationPathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Self-citationVolante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Self-citationSchweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1102 · Cited by 563
“BCPAP PTC V600E b , c WT 229 b , 783 d 457 b , 598 d KTC - 1 PTC 651 d 274 d K1 PTC V600E / WT b WT 627 b 0 b TPC1 PTC WT b , d RET / PTC1 407 b 0 b TT2609 - CO2 FTC 0 d 687 d FTC133 FTC 76 d 298 d ML1 FTC 40 d 205 d WRO82 - 1 FTC V600E b 126 b 0 b 8505C ATC V600E / V600E d ( 82 ) 1 d 580 d SW1736 ATC V600E / WT b WT…”
BackgroundResultInfluentialSelf-citationLito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., Huang, A., Wong, W. L., Callahan, M. K., Merghoub, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.009 · Cited by 562
Self-citationPhase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Self-citationAdeniran, A. J., Zhu, Z., Gandhi, M., Steward, D. L., Fidler, J. P., Giordano, T. J., Biddinger, P. W., & Nikiforov, Y. E. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000176432.73455.1b · Cited by 495
Self-citationAnti-cancer chalcones: Structural and molecular target perspectives
Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.004 · Cited by 495
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Molinaro, E., Romei, C., Biagini, A., Sabini, E., Agate, L., Mazzeo, S., Materazzi, G., Sellari-Franceschini, S., Ribechini, A., Torregrossa, L., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.76 · Cited by 483
Self-citationThe Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., Shibru, D., Bastian, B., & Griffin, A. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148563d · Cited by 480
Update on Fundamental Mechanisms of Thyroid Cancer
Prete, A., Borges de Souza, P., Censi, S., Muzza, M., Nucci, N., & Sponziello, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00102 · Cited by 471
Targeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
Self-citationKnauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
“This mutation can occur early in tumor development, as it is present in papillary microcarcinomas, which are thought to represent an early stage of PTC (8).”
BackgroundInfluentialSelf-citationThyroid carcinoma: molecular pathways and therapeutic targets
Nikiforov, Y. E. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.10 · Cited by 392
Self-citationChakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Self-citationLupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1179 · Cited by 391
Self-citationAnaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
Self-citationRiesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Papillary thyroid carcinoma: an update
LiVolsi, V. A. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.129 · Cited by 353
Pathogenesis, diagnosis and management of thyroid nodules in children
Niedziela, M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.00882 · Cited by 343
Thyroid papillary microcarcinoma: a descriptive and meta-analysis study
Roti, E., degli Uberti, E. C., Bondanelli, M., & Braverman, L. E. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0896 · Cited by 324
New developments in the diagnosis and treatment of thyroid cancer
Schneider, D. F., & Chen, H. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21195 · Cited by 316
Vasko, V., Espinosa, A. V., Scouten, W., He, H., Auer, H., Liyanarachchi, S., Larin, A., Savchenko, V., Francis, G. L., de la Chapelle, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610733104 · Cited by 310
Molecular Diagnostics and Predictors in Thyroid Cancer
Nikiforova, M. N., & Nikiforov, Y. E. (2009) · Thyroid · doi:10.1089/thy.2009.0240 · Cited by 309
Self-citationMelillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
Self-citationTufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012) · Medicine · doi:10.1097/md.0b013e31826a9c71 · Cited by 302
Raf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
Lee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
Labourier, E., Shifrin, A., Busseniers, A. E., Lupo, M. A., Manganelli, M. L., Andruss, B., Wylie, D., & Beaudenon-Huibregtse, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1158 · Cited by 279
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Nikiforova, M. N., & Nikiforov, Y. E. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.83 · Cited by 277
Self-citationBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
Frattini, M., Ferrario, C., Bressan, P., Balestra, D., De Cecco, L., Mondellini, P., Bongarzone, I., Collini, P., Gariboldi, M., Pilotti, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207980 · Cited by 266
Riesco-Eizaguirre, G., Rodríguez, I., De la Vieja, A., Costamagna, E., Carrasco, N., Nistal, M., & Santisteban, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1248 · Cited by 265
BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Salvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
Self-citationMolecular Diagnostics of Thyroid Tumors
Nikiforov, Y. E. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0664-rair.1 · Cited by 257
Self-citationITO, Y., YOSHIDA, H., MARUO, R., MORITA, S., TAKANO, T., HIROKAWA, M., YABUTA, T., FUKUSHIMA, M., INOUE, H., TOMODA, C., et al. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-208 · Cited by 255
Ohori, N. P., Nikiforova, M. N., Schoedel, K. E., LeBeau, S. O., Hodak, S. P., Seethala, R. R., Carty, S. E., Ogilvie, J. B., Yip, L., & Nikiforov, Y. E. (2010) · Cancer Cytopathology · doi:10.1002/cncy.20063 · Cited by 254
Self-citationTrovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
Toward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Strickland, K. C., Howitt, B. E., Marqusee, E., Alexander, E. K., Cibas, E. S., Krane, J. F., & Barletta, J. A. (2015) · Thyroid · doi:10.1089/thy.2014.0612 · Cited by 248
Castro, P., Rebocho, A. P., Soares, R. J., Magalhães, J., Roque, L., Trovisco, V., Vieira de Castro, I., Cardoso-de-Oliveira, M., Fonseca, E., Soares, P., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1336 · Cited by 240
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02605.x · Cited by 238
BRAF(V600E) mutation and the biology of papillary thyroid cancer
Frasca, F., Nucera, C., Pellegriti, G., Gangemi, P., Attard, M., Stella, M., Loda, M., Vella, V, Giordano, C., Trimarchi, F., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0212 · Cited by 232
Differentiated Thyroid Cancer—Treatment: State of the Art
Schmidbauer, B., Menhart, K., Hellwig, D., & Grosse, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061292 · Cited by 205
“In nearly 80% of these tumors the BRAF (V600E) mutation is found [18].”
BackgroundVolante, M., Rapa, I., Gandhi, M., Bussolati, G., Giachino, D., Papotti, M., & Nikiforov, Y. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1233 · Cited by 193
Self-citationTreatment of advanced thyroid cancer with targeted therapies: ten years of experience
Viola, D., Valerio, L., Molinaro, E., Agate, L., Bottici, V., Biagini, A., Lorusso, L., Cappagli, V., Pieruzzi, L., Giani, C., et al. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0555 · Cited by 191
Pathology and genetics of thyroid carcinoma
DeLellis, R. A. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20700 · Cited by 181
“Approximately 15% of poorly differentiated thyroid carcinomas and a significantly higher proportion of undifferentiated/anaplastic carcinomas harbor BRAF mutations [39,40].”
BackgroundDeandreis, D., Al Ghuzlan, A., Leboulleux, S., Lacroix, L., Garsi, J. P., Talbot, M., Lumbroso, J., Baudin, E., Caillou, B., Bidart, J. M., et al. (2011) · Endocrine Related Cancer · doi:10.1677/erc-10-0233 · Cited by 177
“Finally, genetic abnormalities including BRAF and p53 mutations are also involved in tumor aggressiveness and dedifferentiation (Fagin et al. 1993, Nikiforova et al. 2003, Xing 2005, Fugazzola et al. 2006, Durante et al. 2007).”
BackgroundAbubaker, J., Jehan, Z., Bavi, P., Sultana, M., Al-Harbi, S., Ibrahim, M., Al-Nuaim, A., Ahmed, M., Amin, T., Al-Fehaily, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1717 · Cited by 169
Romei, C., Ciampi, R., Faviana, P., Agate, L., Molinaro, E., Bottici, V., Basolo, F., Miccoli, P., Pacini, F., Pinchera, A., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0130 · Cited by 160
Self-citationClinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
“carcinoma components in the same tumour, which both harboured the BRAF mutation.(21,22) However, BRAF mutation is not the only driving force for the formation of undifferentiated”
BackgroundByeon, H. K., Na, H. J., Yang, Y. J., Ko, S., Yoon, S. O., Ku, M., Yang, J., Kim, J. W., Ban, M. J., Kim, J.-H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13480 · Cited by 29
“Multiple genetic mutations or alterations are involved in the tumorigenesis of thyroid cancer, BRAF (V600E) mutation being the most common [1,2].”
BackgroundNew molecular targeted therapies in thyroid cancer
Milano, A., Chiofalo, M. G., Basile, M., Salzano de Luna, A., Pezzullo, L., & Caponigro, F. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000224449.16329.c5 · Cited by 26
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100661 · Cited by 14
Self-citationGenetic mutations, molecular markers and future directions in research
Patel, K. N. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.437 · Cited by 6
Metadata
- Authors
- Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., Santoro, M., Fagin, J. A., & Nikiforov, Y. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-11-01
- Volume
- 88
- Issue
- 11
- Pages
- 5399-5404
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2104875539
- Cited by
- 1,042
- References
- 25
- FWCI
- 32.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.